Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 7/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201031 | 0.83 | STIM1 (0.69) | STIM1ORAI1MEN1KMT2AALDH1A1 | |
| SCHEMBL10201287 | 0.83 | STIM1 (0.43) | STIM1ORAI1GAAMEN1KMT2A | |
| SCHEMBL10201056 | 0.82 | STIM1 (0.82) | STIM1ORAI1KDRMEN1KMT2A | |
| SCHEMBL10201057 | 0.82 | STIM1 (0.82) | STIM1ORAI1KDRMEN1KMT2A | |
| SCHEMBL10256710 | 0.82 | STIM1 (0.56) | STIM1ORAI1GAAKDRMEN1 | |
| SCHEMBL10201043 | 0.81 | STIM1 (0.57) | STIM1ORAI1GAAKDRLIMK1 | |
| SCHEMBL10201061 | 0.81 | STIM1 (0.46) | STIM1ORAI1KDRMEN1KMT2A | |
| SCHEMBL10201072 | 0.79 | STIM1 (0.60) | STIM1ORAI1 | |
| SCHEMBL10201073 | 0.79 | STIM1 (0.60) | STIM1ORAI1GAAABL1 | |
| SCHEMBL17052585 | 0.78 | STIM1 (0.61) | STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GAA 994/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.